|Bid||3.15 x 100|
|Ask||8.88 x 100|
|Day's Range||4.61 - 4.76|
|52 Week Range||3.50 - 6.64|
|PE Ratio (TTM)||-3.16|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||6.57|
Chimerix executives outlined plans for the company’s DNA virus drug and lead product candidate brincidofovir on its first quarter results call Tuesday. The company is continuing to progress a new intravenous formulation of brincidofovir after halting two trials for the drug early last year and cutting 20 percent of its workforce . “In 2018 we plan to have two pivotal trials for brinci - one in short-course oral brinci and one in IV brinci.
The Durham, North Carolina-based company said it had a loss of 38 cents per share. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
NEW YORK, NY / ACCESSWIRE / May 9, 2017 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 8:30 AM Eastern Time. To listen to ...